APRE News
Archived Headlines
- Biotech boom: 6 biotechs are in line to go public starting next week 09/26/19
- Cancer biotech Aprea Therapeutics sets terms for $75 million IPO 09/23/19
- US IPO Weekly Recap: The fall IPO market is looking up as 10 companies launch in a 1-IPO week 09/06/19
- Cancer biotech Aprea Therapeutics files for an $86 million IPO 09/06/19
US IPO Weekly Recap: Oncology biotech Aprea Therapeutics finishes on top in 4-IPO week
Even biotechs aren't immune to the newly-challenging IPO market. Six companies were scheduled to price IPOs this past week, but only four entered the public market; one biotech postponed while another - the largest - withdrew its IPO plans. All four priced at or...read more
Oncology biotech Aprea Therapeutics prices upsized IPO at $15 midpoint
Aprea Therapeutics, a Phase 3 biotech developing targeted therapies for cancer, raised $85 million by offering 5.7 million shares at $15, the midpoint of the $14 to $16 range. The company upsized its offering by 0.67 million shares ($10 million). Aprea...read more
5 biotech IPOs are pricing tonight with 2 more on the calendar
After a wave of biotech launches last week, one more filed terms this week. Seven biotechs are currently on the Renaissance IPO calendar, four of which are targeting billion-dollar valuations. Five are set to price tonight. Swiss biotech ...read more
US IPO Week Ahead: A wave of biotechs and billion-dollar valuations in 6-IPO week
Six IPOs plan to raise $596 million in the week ahead, with two biotechs targeting billion-dollar-plus valuations. Swiss biotech ADC Therapeutics (ADCT) plans to raise $200 million at a $1.8 billion valuation. Insiders have indicated on...read more